Generate Biomedicines, Inc.
Generate Biomedicines, Inc. (NASDAQ: GENB) is trading at $14.91, about ₹1,432 at today's USD/INR rate, as of 28 Sep 2026, 4:00 PM ET, down 1.58% today. Indian residents can buy Generate Biomedicines from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$14.61
Today's high
$15.32
52 week low
$11.00
52 week high
$22.67
GENB opened at $15.15, closed previously at $15.15, and has traded between $11.00 and $22.67 over the past 52 weeks.
About
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Key statistics
Avg. volume
1.05M
Market cap
$1.91B
P/E Ratio
-14.07
Price-to-sales ratio
141.18
Enterprise value
$1.84B
Free cash flow yield
-7.48%
Debt-to-equity ratio
0.14
Return on equity
-108.80%
ROIC
-26.17%
Beta
-0.14
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$31.89M
Earnings per share
-$4.98
Free cash flow
-$204.13M
Net profit margin
-950.66%
Gross margin
75.82%
EBITDA
-$208.49M
Revenue growth
55.89%
How to buy Generate Biomedicines from India
Indian residents can buy Generate Biomedicines shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for Generate Biomedicines and place an order
Find Generate Biomedicines by name or by its ticker, GENB, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Generate Biomedicines trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Generate Biomedicines position in USD and INR. Generate Biomedicines pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Generate Biomedicines from India
Trading and taxes when buying Generate Biomedicines from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneGenerate Biomedicines does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy Generate Biomedicines stock?
Yes. Generate Biomedicines (GENB) has been listed on NASDAQ since 2026, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one Generate Biomedicines share cost in rupees?
One Generate Biomedicines share is $14.91 — about ₹1,432 at a USD/INR rate of 96.07 on 28 Sep 2026. Both the Generate Biomedicines price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Generate Biomedicines from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of Generate Biomedicines?
Yes. One Generate Biomedicines share is $14.91, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Generate Biomedicines.
How are gains on Generate Biomedicines shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Generate Biomedicines price. Paasa issues a capital-gains statement for your return.
Does Generate Biomedicines pay a dividend?
No. Generate Biomedicines does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Generate Biomedicines from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on Generate Biomedicines shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare Generate Biomedicines shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Generate Biomedicines holding, its cost and its closing value.
How do I sell Generate Biomedicines and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.